All In Biotech

Drug Trial Radar · NCT05249426

A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

An Open Label Trial of BI 765063 in Combination With BI 754091 (Ezabenlimab) Alone or With BI 836880, Chemotherapy, or Cetuximab, in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) or Hepatocellular Carcinoma (HCC)

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Apr 12, 2022

Primary completion

Jul 15, 2024

Study completion Jun 22, 2026

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Feb 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

With an amendment of the protocol, this study is only open to adults with head and neck cancer. Previously also adults with liver cancer joined. This is a study for people for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find out whether combining different medicines make tumours shrink. The tested medicines in this study are antibodies that act in different ways against cancer. BI 765063 and ezabenlimab may help the immune system fight cancer (checkpoint inhibitors). Cetuximab blocks growth signals and may prevent the tumour from growing. BI 836880 blocks the formation of new blood vessels that the tumour needs to grow. With amendments of the protocol, all participants receive cetuximab in addition to BI 765063 and ezabenlimab. Ezabenlimab treatment and any other assigned treatment are given no longer than 2 years. Previously, BI 765063 and ezabenlimab were also given alone, or in combination with chemotherapy, or with BI 836880. BI 765063, ezabenlimab, and BI 836880 are given as infusions into veins every 3 weeks. Cetuximab is given as an infusion every 1 or 2 weeks. Participants can stay in the study as long as they benefit from treatment and can tolerate it. They regularly visit the study site where doctors check participants' health and take note of any unwanted effects. The doctors also monitor the size of the tumour.

Conditions

  • Head and Neck Squamous Cell Carcinoma (HNSCC)

Interventions

  • BI 765063Drug

    BI 765063 (anti-Signal Regulatory Protein Alpha (SIRPα) Monoclonal Antibody (mAb))

  • EzabenlimabDrug

    Ezabenlimab (anti-Programmed cell death protein 1 (PD-1) Monoclonal Antibody (mAb))

  • BI 836880Drug

    BI 836880 (anti-Vascular Endothelial Growth Factor (VEGF) / Angiopoetin 2 (Ang2))

  • CetuximabDrug

    Cetuximab

  • Investigator´s Choice ChemotherapyOther

    Allowable chemotherapies include: paclitaxel, docetaxel, capecitabine, 5-fluorouracil, methotrexate or combinations thereof

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response (OR)Time frame: Up to 24 months.

Locations

25 sites in 11 countries. Site status is shown where the registry gives one.

  • Valkyrie Clinical Trials

    Los Angeles, California

  • CTR Georges-François Leclerc

    Dijon, France

  • CTR Leon Berard

    Lyon, France

  • HOP Timone

    Marseille, France

  • INS Curie

    Paris, France

  • HOP Civil

    Strasbourg, France

  • INS Claudius Regaud IUCT-Oncopole

    Toulouse, France

  • Japanese Foundation for Cancer Research

    Tokyo, Koto-ku, Japan

  • Hospital Sultan Ismail

    Johor Bahru, Malaysia

  • Sarawak General Hospital

    Kuching, Sarawak, Malaysia

  • ARKE SMO S.A. de C.V

    Mexico City, Mexico

  • FAICIC S de RL de C.V.

    Veracruz, Mexico

  • Investigacion Biomedica para el Desarrollo de Farmacos, S.A. de C.V.

    Zapopan, Mexico

  • ARENSIA Exploratory Medicine

    Chisinau, Moldova

  • Mandziuk Slawomir Specialist Medical Practice

    Lublin, Poland

  • "Prof. Dr. Alexandru Trestioreanu" Oncology Institut

    Bucharest, Romania

  • Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca

    Cluj-Napoca, Romania

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Duran i Reynals

    L'Hospitalet de Llobregat, Spain

  • Hospital Clínico San Carlos

    Madrid, Spain

  • King Chulalongkorn Memorial Hospital

    Bangkok, Thailand

  • Songklanagarind Hospital

    Songkhla, Thailand

  • King's College Hospital

    London, United Kingdom

  • The Royal Marsden Hospital, Chelsea

    London, United Kingdom

  • Hammersmith Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.